Panomics Analysis Service & Solution


PASS is an analysis solution optimized for academia and pharma research.
The proprietary solution was derived from proven technology and innovation
embedded in Mastocheck, a proteomics-based early cancer diagnostics approved
by Ministry of Food and Drug Safety (MFDS).

Bertis PASS

We will see that the future of health care AI and the key for a healthier future may, in part, lie in pan-omics

We will see that the future of health care AI and the key for a healthier future may, in part, lie in panomics (Forbes, Sep 2019)

PASS is a platform for integrative analysis of pan-omics data, based on our proven and reliable bioinformatics analysis capabilities. Our team consists of experienced scientists with an extensive track record of research achievements spanning more than a decade in mass spectrometry-based proteomics.

Bertis possesses the core expertise and proprietary technology for pan-omics (multi-omics) analysis to provide customized solutions in all fields where omics data analysis is applicable.

With PASS, you can leverage Bertis’ scientific resources and cutting-edge tools to advance your research projects and goals, from the design stage to the interpretation and visualization of bioinformatics analysis results.

Global proteomics
(Cell, Tissue, blood proteome)
Companion Diagnostics (CDx)
Exosome Therapeutics Quality Control
Service Brochure
Global proteomics (Cell, Tissue, blood proteome)

Label-free quantification of peptide/protein

Label-free analysis based on data-independent acquisition (DIA)
Our industry-leading protein analysis of non-depleted plasma can result in 1,300 protein identifications in one-hour per single sample.

Our isotope-labeling enables a sample-to-sample comparison analysis in protein quantification.

Bertis labeling quantification and advanced fractionation technology enable industry-leading protein quantification analysis in cell or tissue samples.

Our phospho/glyco proteomics ensures high-quality post-translational modification (PTM) analysis of proteins, providing an optimized solution for biomarker discovery and mechanism of action analysis.

Our bioinformatics analysis provides results specifically tailored to research purposes.

Our bioinformatics analysis provides your research needs from basic analysis of protein composition and quantification to in-depth systems biology analysis.
We provide analysis services that meet our customer’s needs through continuous communication and interaction.

  • Protein identification and quantification

    Report on the qualitative and quantitative information of proteins present in samples

  • Differential expression analysis

    Identification of proteins with statistically significant differences in expression levels

  • Gene ontology analysis

    Analysis of cellular mechanisms, molecular functions, and subcellular localization

  • Pathway analysis

    Interpretation of subcellular mechanisms through biological pathway analysis

  • Post-translational modification (PTM) analysis

    Phosphorylation and glycosylation analysis at proteomic levels

  • Multi-omics integration: DNAs, RNAs, Proteins, Metabolites

    Analysis and interpretation of correlation between proteomics and other omics data

Clustering analysis
Pathway analysis
Differential expression analysis
Service Brochure
Companion Diagnostics (CDx)

We provide a companion diagnostic solution through pathway analysis based on RNA and protein quantification information respective to subtypes from each diseases.

For precision medicines developed based on multi-omics analysis, biomarkers can be used to identify target patients in advance. Global pharmaceutical companies are active in the use of companion diagnostics as a key strategic tool in clinical development programs.

PASS provides solutions for the entire process from discovery of drug candidates to non-clinical to clinical trials through pan-omics technology.

Success rates in clinical trials depending on the use of biomarkers (2011-2020)

BIO, Informa Pharma Intelligence, QLS Advisors (2021) Clinical Development Success Rates and Contributing Factors 2011 – 2020

Bertis has array of innovative and reliable technology to increase the safety and efficacy of an investigational drug across the clinical research landscape, including solutions for the discovery of biomarkers for companion diagnostics and the determination of clinical targets through functional analysis.

Discovery Stage

Cell line & Drug Candidate specific biomarker

  • Cell line-dependent biomarker identification
  • Identification of molecular subtypes and biomarker discovery on the basis of pan-omic analysis of cell lines
  • Efficacy or safety check for each cell line after drug candidate processing: MoA confirmation

Pre-Clinical Stage

Animal model classification and efficacy/safety analysis through a drug specific biomarker

  • Subtyping and establishment of biomarkers for each subtype based on the pan-omics data from clinical specimen
  • Identification of drug-specific subtypes based on changes in each biomarker after drug candidate processing
  • Establish an evidence, such as dosage and dosing period of a drug candidate through biomarker expression
Service Brochure
Exosome Therapeutics Quality Control

Exosomes contain proteins, lipids, nucleic acids, and metabolites, and can be easily enriched from biofluids, providing very valuable information for early detection and monitoring of diseases.

The Ministry of Food and Drug Safety requires RNA, lipid and proteomic analyses in its guidelines for the development of exosome therapeutics, and PASS provides these analyses in an all-in-one package.

MFDS Guidelines for Extracellular Vesicle Therapeutics

Exosome RNA Sequencing

PASS enables rapid and efficient isolation of RNAs and profiling of exosome nucleic acids using qRT-PCR and novel sequencing methods.

Exosome Lipidomics

We perform high-reliability and high-sensitivity analysis through an ultra-high-performance tool (UPLC, Orbitrap Exploris 480 MS) and lipid analysis experts who have been producing and interpreting analysis data for many years.

Exosome Proteomics

PASS offers and performs quantification analysis that meets customer needs based on the unique expertise in exosome protein extraction.
We provide reliable results through deep profiling of exosome proteome and a specialized data library. Our world-class bioinformatics research team at Bertis reviews and interprets pan-omics data (RNA/Lipid) to support in-depth research.

Service Brochure
Protein Characterization (Physicochemical property of proteins)

Our structure analysis using mass spectrometry provides results that meet the requirements of the FDA, the MFDS and other regulatory authorities regarding novel therapies or biosimilars.

Based on basic amino acid analysis (full sequencing), we perform post-translational modification (PTM) analysis, which is important for protein potency and stability. In this regard, we can perform test methods based on design of experiment (DOE) statistical methodology and deliver documents to be submitted to regulatory authorities.

Protein identification and quantification

Structural analysis of all types of protein therapeutics, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), and enzymes

  • Full Length-Amino acids sequencing

    Peptide identification of each peak through peptide mapping (MS spectrum confirmation, MS/MS spectral analysis with 100% AA matches)

    Improved N- and C-terminal sequencing of proteins

Post-translational modification (PTM)

More reliable results based on design of experiment (DOE) statistical methodology to perform the experiments systematically and analyze data efficiently

  • Disulfide bond analysis

    Disulfide bond ID Total possible lankage analysis

  • Deamidation identification and quantification
  • Phosphorylation identification and quantification , phospho-proteomic analysis
  • Other functional modifications


Single protein analysis and research of protein complexes with glycosylation closely related to biological function and toxicity as well as structural stability of proteins

  • Glycosylation site determination
  • Glycan profiling
  • Site-specific glycan identification and quantification
  • Glycomics research with glycan enrichment
Please use this form to submit your inquiry for Bertis PASS. We will be happy to review your request and respond in a timely manner.
Privacy Policy
By registering your details on our website, you consent to us collecting personal information for the purpose of responding to your inquiries. We understand the importance of protecting your privacy and will not use your personal information for anything other than to answer your inquiries.

I consent to the collection and use of my personal information collected by Bertis through legitimate channels for the purposes outlined in this policy.

  • Personal information collected: Your Name, Email, Contact, Company Name, Occupation
  • Purpose of data collection and use: Confirm the delivery of customer inquiries, contact the inquirer for fact checking, provide answers, notify inquiry results
  • Period of retention and use of personal information: To be retained for one year after the purpose of collection and use of personal information is met

* You have the right to refuse to consent to the collection and use of your personal information, and if you do not agree to these terms, your access to the service may be restricted.
* Your personal information will be destroyed without delay one year after the purpose of collecting and using personal information is met. However, if there is a duty to preserve personal information in accordance with Korean law or ordinance, it will be preserved for a certain period specified by the law.
  • Basis for data retention: Records on contract or subscription withdrawal, etc.
  • Retention period: 5 years

** Records of contracts, withdrawal of subscription, etc.: 5 years (Act on the Consumer Protection in Electronic Commerce, etc.)
** Records of payment and supply of goods, etc.: 5 years (Act on the Consumer Protection in Electronic Commerce, etc.)
** Records of handling customers’ complaints or disputes: 3 years (Act on the Consumer Protection in Electronic Commerce, etc.)

go top